SIRT1 and prostate carcinoma: In addition, SIRT1 overexpression has been shown to correlate with poor prognosis in several cancer types, including large B-cell lymphoma (21), prostate cancer (18,22), pancreatic cancer (23), gastric cancer (24,25), breast cancer (26), hepatocellular carcinoma (27), colorectal cancer (28) and lung cancer (29).